Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT05935748
PHASE2

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Sponsor: NiKang Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.

Official title: A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2023-07-28

Completion Date

2025-09-04

Last Updated

2026-11-12

Healthy Volunteers

No

Interventions

DRUG

NKT2152

Oral HIF2a inhibitor

DRUG

palbociclib

a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

OTHER

sasanlimab

an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration

Locations (8)

University of California San Diego

La Jolla, California, United States

Northwestern University - Feinberg School of Medicine

Chicago, Illinois, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan-Rogel Cancer Center

Ann Arbor, Michigan, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

UT Southwestern Medical Center

Dallas, Texas, United States

University of Virginia Health System

Charlottesville, Virginia, United States